CA2201628A1 - Parenteral pharmaceutical compositions containing gf120918a - Google Patents

Parenteral pharmaceutical compositions containing gf120918a

Info

Publication number
CA2201628A1
CA2201628A1 CA002201628A CA2201628A CA2201628A1 CA 2201628 A1 CA2201628 A1 CA 2201628A1 CA 002201628 A CA002201628 A CA 002201628A CA 2201628 A CA2201628 A CA 2201628A CA 2201628 A1 CA2201628 A1 CA 2201628A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
safe
effective amount
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002201628A
Other languages
English (en)
French (fr)
Inventor
Wei-Qin Tong
Mickey Lee Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2201628A1 publication Critical patent/CA2201628A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002201628A 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a Abandoned CA2201628A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31830894A 1994-10-05 1994-10-05
US08/318,308 1994-10-05

Publications (1)

Publication Number Publication Date
CA2201628A1 true CA2201628A1 (en) 1996-04-18

Family

ID=23237614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002201628A Abandoned CA2201628A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a

Country Status (12)

Country Link
EP (1) EP0784474A2 (pt)
JP (1) JPH10507177A (pt)
KR (1) KR970705997A (pt)
AU (1) AU702519B2 (pt)
BR (1) BR9509251A (pt)
CA (1) CA2201628A1 (pt)
CZ (1) CZ104197A3 (pt)
HU (1) HUT77883A (pt)
NZ (1) NZ295546A (pt)
PL (1) PL319511A1 (pt)
RU (1) RU2157687C2 (pt)
WO (1) WO1996011007A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
DE60045114D1 (de) 1999-05-17 2010-11-25 Cancer Res Ventures Ltd Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
ES2253398T3 (es) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
WO2003002150A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体

Also Published As

Publication number Publication date
WO1996011007A1 (en) 1996-04-18
PL319511A1 (en) 1997-08-18
HUT77883A (hu) 1998-09-28
AU702519B2 (en) 1999-02-25
NZ295546A (en) 1999-01-28
CZ104197A3 (en) 1997-09-17
JPH10507177A (ja) 1998-07-14
AU3891395A (en) 1996-05-02
KR970705997A (ko) 1997-11-03
MX9702473A (es) 1997-07-31
EP0784474A2 (en) 1997-07-23
BR9509251A (pt) 1997-10-21
RU2157687C2 (ru) 2000-10-20

Similar Documents

Publication Publication Date Title
EP1052974B1 (en) Pharmaceutical formulation containing epothilone
US10688111B2 (en) Liquid formulations of compounds active at sulfonylurea receptors
EP2616076B1 (en) Pharmaceutical compositions
US20080293796A1 (en) Parenteral and oral formulations of benzimidazoles
ES2451540T3 (es) Formas de dosificación oral de bendamustina
US11779585B2 (en) Method for treating coronavirus infections
BG66494B1 (bg) Методи за получаване на фармацевтични състави, съдържащи епотилонови аналози за лечение на рак
AU702519B2 (en) Parenteral pharmaceutical compositions containing GF120918A
WO2016046786A1 (en) Long acting pharmaceutical compositions
US20230404918A1 (en) Fulvestrant formulations and methods of their use
EP2310009B1 (en) Parenteral and oral formulations of benzimidazoles
EP3509569A1 (en) Sterile injectable compositions comprising drug micelles
KR101679380B1 (ko) 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
WO2005021046A1 (en) Compositions and methods for delivery of biologically active agents
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
WO2012001494A2 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
RU2236227C1 (ru) Устойчивая фармацевтическая форма противоракового препарата
WO2012029076A2 (en) Stable pharmaceutical composition
MXPA97002473A (en) Parenteral pharmaceutical compositions containing gf1209
CN1164189A (zh) 含有gf120918a的非肠道药物组合物
WO2024127418A1 (en) Injectable compositions of posaconazole
EP4025205A1 (en) Cabazitaxel liquid formulations
JP2024537910A (ja) 安定した希釈準備済みカルフィルゾミブ組成物
WO2018109731A1 (en) Pharmaceutical compositions of taxane and its derivatives
AU2004267882A1 (en) Compositions and methods for delivery of biologically active agents

Legal Events

Date Code Title Description
FZDE Discontinued